28 January 2016
XCYST is the successor of REFLUX 500 mg, which has not been available since August 2015. XCYST is licensed (NL-RVG 04480) for the same indication as REFLUX: treatment of uncomplicated urinary tract infections.
In the Netherlands, XCYST is supplied since February 2016 via the pharmaceutical wholesalers. For information about the availability outside the Netherlands, visit the XCYST productpage (left dropdown menu).
We have listed the most important changes.
Like REFLUX, XCYST tablets are gastric acid resistant. While REFLUX was available as dragee (sugar coating), XCYST tablets have a film coating. This makes the tablet look quite different. The composition of the tablet (active substance and excipients) and the efficacy have remained the same.
The cartons of XCYST are well recognisable. XCYST is supplied in containers with 120 tablets. Both the label and the folding carton are yellow.
Based on current stability data, XCYST has a shelf life of 24 months after manufacturing date (store below 25 °C).